2016 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
12/22/16NeuroDerm Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
REHOVOT, Israel, Dec. 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the closing of the offering of an additional 600,000 shares at a public offering price of $18.75 pursuant to the underwriters’ option to purchase additional shares in its recently completed public offering. All of the ordinary shares were issued and sold by NeuroDerm. The underwriters exercised in fu... 
Printer Friendly Version
12/22/16NeuroDerm Announces Completion of Patient Enrollment and Treatment in a Phase II Trial of ND0612H for Advanced Parkinson’s Disease
- First evaluation of clinical efficacy of ND0612H in advanced Parkinson's patients - REHOVOT, Israel, Dec. 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that it completed patient enrollment and treatment in trial 006 of ND0612H, the company's continuously administered levodopa/carbidopa (LD/CD) solution. ND0612H, administered subcutaneously through a belt pump, is... 
Printer Friendly Version
12/12/16NeuroDerm Announces Closing of a Follow-On Offering of Ordinary Shares
REHOVOT, Israel, Dec. 12, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the closing of its previously announced follow-on offering of 4,000,000 shares of its ordinary shares at a price to the public of $18.75 per share. All of the ordinary shares were issued and sold by NeuroDerm. In addition, NeuroDerm has granted the underwriters a 30-day option to purchase up to an ad... 
Printer Friendly Version
12/07/16NeuroDerm Announces Pricing of a Follow-On Offering of Ordinary Shares
REHOVOT, Israel, Dec. 07, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the pricing of a follow-on offering of 4,000,000 shares of its ordinary shares at a price to the public of $18.75 per share. All of the ordinary shares are being offered by NeuroDerm. In addition, NeuroDerm has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares at... 
Printer Friendly Version
12/06/16NeuroDerm Announces Launch of a Follow-On Offering of Ordinary Shares
REHOVOT, Israel, Dec. 06, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the launch of a follow-on offering of its ordinary shares. All of the ordinary shares will be offered by NeuroDerm. The company expects to use the net proceeds of the offering to fund ongoing and planned clinical trials for its product candidates and the development of related devices and for researc... 
Printer Friendly Version
12/05/16NeuroDerm to Replace Two Phase 3 Clinical Trials with Small Pharmacokinetic Trials Following FDA Meeting on ND0612 Regulatory Development
- Company to pursue comparative bioavailability regulatory route instead of clinical efficacy development route - - NeuroDerm to add patients to its long-term safety trial - - Conference call and webcast today at 8:00 a.m. ET - REHOVOT, Israel, Dec. 05, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that following its End-of-Phase 2 meeting with the United States Food... 
Printer Friendly Version
12/02/16NeuroDerm Announces Top-Line Results of Pilot PK Trial Comparing ND0701 with Commercial Apomorphine
Regulatory Development of ND0701 in the EU to Proceed Based on PK Similarity for the Treatment of Parkinson’s Disease REHOVOT, Israel, Dec. 02, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical Company developing drugs for central nervous system (CNS) disorders, today announced the completion of a pilot study (trial 101) in healthy subjects comparing the pharmacokinetics (PK) of ND0701, the Company’s proprietary continuous, subcutaneously delivered apomorp... 
Printer Friendly Version
11/10/16NeuroDerm Announces Third Quarter 2016 Financial Results
Company to host conference call and webcast today at 8:30 a.m. ET REHOVOT, Israel, Nov. 10, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the third quarter ended September 30, 2016 and provided a corporate update. “Throughout the third quarter we continued to execute our strategic development plans for multiple product candidates within our portfo... 
Printer Friendly Version
11/03/16NeuroDerm CEO to Present at Upcoming Investor Conferences
REHOVOT, Israel, Nov. 03, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the following investor conferences: Stifel 2016 Healthcare Conference taking place in New York, from November 15 – 16, 2016. Dr. Lieberman’s presentation will take place on Tuesday, November 15 at 9:30am ET. Jefferies 2016 London Healthcar... 
Printer Friendly Version
11/01/16NeuroDerm to Host Third Quarter 2016 Financial Results Conference Call on November 10, 2016
REHOVOT, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will report financial results for the third quarter of 2016 before the market opens on Thursday, November 10, 2016.  Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update. To access the call, dial 844-452-2810 (U.... 
Printer Friendly Version
09/29/16NeuroDerm Provides Updates on ND0612 Long-Term Safety Trial and Submission of Marketing Applications
REHOVOT, Israel, Sept. 29, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that the Company requires additional time to activate clinical sites in certain countries that are participating in its long-term safety trial (trial 012, the "BeyoND" trial) of ND0612, the Company’s continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid formulation.  As previously ... 
Printer Friendly Version
09/22/16NeuroDerm’s ND0612 Mini-Pump Delivery System Successfully Used by Parkinson’s Disease Patients in Home Setting
- Data Presented at 4th World Parkinson Congress - REHOVOT, Israel, Sept. 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today reported human factors data from a usability study focused on the interactions between Parkinson’s disease (PD) patients and the mini-pump device used to administer ND0612, the Company’s continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid... 
Printer Friendly Version
09/19/16NeuroDerm to Present ND0612 Data at 4th World Parkinson Congress Demonstrating Ease of Use of Mini-Pump Delivery System
REHOVOT, Israel, Sept. 19, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that the Company will present previously unreported human factors data from a usability study focused on the interactions between Parkinson’s disease patients and the mini-pump device used to administer ND0612, the Company’s continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid for... 
Printer Friendly Version
08/25/16NeuroDerm Announces Second Quarter 2016 Financial Results and Provides Corporate Update
Company to host conference call and webcast today at 8:30 a.m. ET REHOVOT, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the second quarter ended June 30, 2016 and provided a corporate update. “We have been very productive in recent months advancing our clinical programs and moving closer toward our goal of providing a less inva... 
Printer Friendly Version
08/25/16NeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of Parkinson’s Disease
Number of patients targeted for enrollment reduced based on observed and anticipated treatment effect REHOVOT, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that it has initiated enrollment of Parkinson's disease (PD) patients in a Phase III efficacy trial (trial 007, named the "iNDiGO" trial) of ND0612L, the company’s low-dose continuous, subcutaneous... 
Printer Friendly Version
08/11/16NeuroDerm to Host Second Quarter 2016 Financial Results Conference Call on August 25, 2016
REHOVOT, Israel, Aug. 11, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will report financial results for the second quarter of 2016 before the market opens on Thursday, August 25, 2016.  Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update. To access the call, dial 844-452-2810 (U.S.)... 
Printer Friendly Version
07/27/16NeuroDerm Announces Issuance of a New U.S. Patent for Aqueous Apomorphine Covering Concentrated Subcutaneously Delivered Pharmaceutical Compositions
REHOVOT, Israel, July 27, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,381,249, which claims aqueous pharmaceutical compositions comprising apomorphine, and relates to the Company’s ND0701 program. ND0701's formulation, containing concentrated apomorphine-base, is intended for chronic therapy of Par... 
Printer Friendly Version
07/26/16NeuroDerm Announces Start of Bioequivalence Trial in Healthy Volunteers of ND0701, a New Continuous Subcutaneously Delivered Apomorphine Product Candidate for the Treatment of Advanced Parkinson’s Disease
- ND0701 complements the company’s product pipeline for the treatment of advanced Parkinson's disease - - ND0701's proprietary formulation is designed to improve patient convenience by allowing delivery through a small, disposable, low-volume patch-pump and improve the tolerability and pain associated with current continuous apomorphine therapy - - Company pursuing an abbreviated EU regulatory pathway based on demonstrating bioequivalence vs. commercially available apomorphine in healthy vol... 
Printer Friendly Version
07/06/16NeuroDerm Announces Additions to Management Team
REHOVOT, Israel, July 06, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced the appointments of Tami Yardeni as Chief Operating Officer and Eran Shor as Vice President (VP) Devices.  Ms. Yardeni joins us from Teva Pharmaceutical Industries, where she worked for the past 17 years, most recently as VP, Head of Global Clinical Operation, Global R&D.  In this position she wa... 
Printer Friendly Version
07/05/16NeuroDerm to Present at the Cantor Fitzgerald Healthcare Conference on July 13
REHOVOT, Israel, July 05, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that Oded S. Lieberman, PhD, CEO will present at the Cantor Fitzgerald Healthcare Conference on Wednesday, July 13 at 11:45am ET in New York.  Dr. Lieberman will provide a corporate overview and review recent and upcoming company milestones. To access the live webcast of the presentation, please v... 
Printer Friendly Version
06/30/16NeuroDerm Announces Start of U.S. Patient Enrollment in Trial 006, a Phase II Trial of ND0612H for Advanced Parkinson’s Disease
Expansion of Ongoing Multicenter International Trial to Sites in the U.S. to Support Broad Regulatory Development Strategy of Subcutaneously Delivered Liquid Levodopa/Carbidopa for Patients with Advanced Parkinson’s Disease REHOVOT, Israel, June 30, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced the start of patient enrollment in the United States in an ongoing phase II... 
Printer Friendly Version
06/28/16NeuroDerm Announces ND0612H Achieves Comparable Pharmacokinetics to DUODOPA® in Head-To-Head Pilot PK Comparison Trial
- Company to Proceed with Regulatory Development of ND0612H Based on PK Similarity for the Treatment of Parkinson’s Disease in EU –     - Company to Host Conference Call and Webcast Today at 8:30 a.m. ET - REHOVOT, Israel, June 28, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that topline results from Trial 005, a pilot, dose-finding pharmacokinetic (PK) study on he... 
Printer Friendly Version
06/24/16NeuroDerm Added to Russell Global Index
REHOVOT, Israel, June 24, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the company has been selected to join the Russell Global Index as part of the annual Russell Equity Index Reconstitution, effective as of June 27. Membership in the Russell Global Index, which remains in place for one year, means automatic inclusion in the appropriate large-cap, small-cap, al... 
Printer Friendly Version
06/23/16NeuroDerm Presents Three Posters at the 20th International Congress of Parkinson’s Disease and Movement Disorders
- Data Presented in the Posters Included Data on the Company’s New Apomorphine Product Candidate (ND0701) as well as Study Design of the First ND0612H Efficacy Trial (Trial 006) and Additional Data on the Effect of Continuous Subcutaneous Carbidopa Administration on Levodopa Plasma Levels - REHOVOT, Israel, June 23, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today presented pre-clin... 
Printer Friendly Version
06/16/16NeuroDerm to Present Design of the First Clinical Efficacy Study of ND0612H and Other Clinical Data at the 20th International Congress of Parkinson’s Disease and Movement Disorders
- Clinical Trial Evaluating Efficacy, Safety, Tolerability and Pharmacokinetics of Two Dosing Regimens of ND0612 Compared With Oral Standard of Care Treatment in Patients With Advanced Parkinson’s Disease - - Clinical and Pre-Clinical Data Investigating the Effect of Continuous Carbidopa Administration on Levodopa Plasma Levels Also Selected for Presentation - - Preclinical Data for ND0701, NeuroDerm’s Investigational Continuous Subcutaneous Apomorphine Formulation for Advanced Parkinson’s D... 
Printer Friendly Version
05/31/16NeuroDerm CEO to Present at Jefferies 2016 Healthcare Conference on June 7
REHOVOT, Israel, May 31, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the Jefferies 2016 Healthcare Conference on Tuesday, June 7, at 2:30pm ET in New York.  Dr. Lieberman will give a corporate overview and discuss the company's next-generation treatments for central nervous system disorders, including the company's flagsh... 
Printer Friendly Version
05/26/16NeuroDerm Announces First Quarter 2016 Financial Results
Company to Host Conference Call and Webcast Today at 8:30 a.m. ET REHOVOT, Israel, May 26, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the first quarter ended March 31, 2016. “We are pleased with the recent initiation of our long-term safety trial for ND0612L and ND0612H, and remain on track to achieve our development milestones in 2016 for ou... 
Printer Friendly Version
05/17/16NeuroDerm to Host First Quarter 2016 Financial Results Conference Call on May 26, 2016
REHOVOT, Israel, May 17, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will report financial results for the first quarter of 2016 before the market opens on Thursday, May 26, 2016.  Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update. To access the call, dial 844-452-2810 (U.S.) or 5... 
Printer Friendly Version
05/09/16NeuroDerm Announces Patient Enrollment in Long-Term Safety Trial of ND0612 for Parkinson’s Disease
- Trial to Provide Safety Data to Support U.S. and EU Regulatory Applications of Liquid Levodopa/Carbidopa Lead Product Candidate - REHOVOT, Israel, May 09, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced the start of patient enrollment in a long-term safety study (trial 012) of the company’s continuously administered subcutaneous levodopa/carbidopa (LD/CD) formulation u... 
Printer Friendly Version
05/05/16NeuroDerm Announces 2016 Annual General Meeting of Shareholders
REHOVOT, Israel, May 05, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will hold its 2016 Annual General Meeting of Shareholders on Tuesday, June 14, 2016 for the purposes of (i) re-electing its Class II directors, Shmuel Cabilly and Larry Ellberger, for a three-year term, (ii) ratifying the re-appointment of Kesselman & Kesselman, a member firm of Pricewaterhous... 
Printer Friendly Version
04/22/16NeuroDerm Announces Removal of FDA Import Alert of Infusion Pumps Used in ND0612 Clinical Trials
REHOVOT, Israel, April 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the Company has been informed by Canè S.p.A., the third party manufacturer of the infusion pumps used to deliver ND0612 in its current clinical trials, that they have been removed from the list of companies under import alert.  This latest regulatory action by the U. S. Food and Drug Administra... 
Printer Friendly Version
04/05/16NeuroDerm Parkinson’s Disease Clinical Data Selected for Two Oral Presentations at the American Academy of Neurology 68th Annual Meeting
- An Encore Presentation on ND0612 Will be Given at the Invited Science: Movement Disorders Session Following the Identification of ND0612 Stable Levodopa Plasma Levels as a Critical Advance in the Field of Neuroscience - - A Platform Presentation on the Effects of Continuously Delivered Carbidopa on Levodopa Bioavailability Compared to Oral Carbidopa Will Also be Presented at the Movement Disorders: Parkinson’s Disease Clinical Trials and Therapeutics Session - REHOVOT, Israel, April 05, 2... 
Printer Friendly Version
03/31/16NeuroDerm Announces Fourth Quarter and Full Year 2015 Financial Results and Provides a Corporate Update
- Company to Host Conference Call and Webcast Today at 8:30 a.m. ET - REHOVOT, Israel, March 31, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the fourth quarter and 2015 fiscal year ended December 31, 2015. “In the past year, we made solid progress advancing our lead product candidates ND0612L and ND0612H for the treatment of moderate to severe... 
Printer Friendly Version
03/22/16NeuroDerm to Host Fourth Quarter and 2015 Fiscal Year Financial Results Conference Call on March 31, 2016
REHOVOT, Israel, March 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will report financial results for the fourth quarter and fiscal year of 2015 before the market opens on Thursday, March 31, 2016.  Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update. To access the call, dial 877... 
Printer Friendly Version
03/02/16NeuroDerm to Present at Upcoming Investor Conferences
REHOVOT, Israel, March 02, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the following investor conferences: Cowen and Company 36th Annual Health Care Conference taking place in Boston, Massachusetts from March 7 – 9, 2016.  Dr. Lieberman’s presentation will take place on Wednesday, March 9, at 11:20am ET. 28th ... 
Printer Friendly Version
01/04/16NeuroDerm CEO to Present at the 34th Annual J.P. Morgan  Healthcare Conference on January 14, 2016
REHOVOT, Israel, Jan. 04, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 11:00am PT in San Francisco.  Dr. Lieberman will give a corporate overview and discuss the company's flagship product candidates designed to treat moderate to severe Parkinson'... 
Printer Friendly Version